NCT06417736 Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
| NCT ID | NCT06417736 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University |
| Condition | Endometrial Cancer Stage I |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2023-12-01 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the effect and adverse side effects of membrane-inhibiting formula plus oral progestins as fertility-preserving treatment in patients with early-stage endometrial cancer and endometrial hyperplasia research questions：When taken with oral progestins, does the drug membrane-inhibiting formula shorten the time required for complete endometrial remission? What medical problems do participants have when taking drug membrane-inhibiting formula plus oral progestins? Efficacy, side effects, recurrence, pregnancy, and time to obtain pregnancy in different molecular classifications of POLE-mutated, mismatch repair-deficient(MMRd), p53 wild type(p53wt), and p53-abnormal(p53abn). Participants will: Take drug membrane-inhibiting formula plus oral progestins every day Visit the clinic once every 3 months for checkups, tests, and hysteroscopy Keep a diary of examination results and pathology
Eligibility Criteria
Inclusion Criteria: * 1.18-45 years old with a strong desire to preserve fertility; 2. pathologically diagnosed with primary grade1 or grade2 endometrioid endometrial carcinoma and hyperplasia 3.no signs of suspicious myometrial invasion by enhanced magnetic resonance imaging (MRI) 4. no signs of suspicious extrauterine metastasis by enhanced computed tomography and CT scan of the Lungs Exclusion Criteria: * 1.have contraindication for pregnancy. 2.no fertility requiremen 3.have myometrial invasion or extrauterine metastasis 4.pathologically diagnosed with primary grade3 endometrioid endometrial carcinoma or non-endometrioid endometrial carcinoma 5.Any disease or symptom that may affect the implementation of the study or the interpretation of the results
Contact & Investigator
Yang Li, Doctor
PRINCIPAL INVESTIGATOR
Women's Hospital School Of Medicine Zhejiang University
Frequently Asked Questions
Who can join the NCT06417736 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Endometrial Cancer Stage I. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06417736 currently recruiting?
Yes, NCT06417736 is actively recruiting participants. Contact the research team at 5516015@zju.edu.cn for enrollment information.
Where is the NCT06417736 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06417736 clinical trial?
NCT06417736 is sponsored by Women's Hospital School Of Medicine Zhejiang University. The principal investigator is Yang Li, Doctor at Women's Hospital School Of Medicine Zhejiang University. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.